Target Name: WFDC5
NCBI ID: G149708
Review Report on WFDC5 Target / Biomarker Content of Review Report on WFDC5 Target / Biomarker
WFDC5
Other Name(s): WAP1 | WAP four-disulfide core domain 5, transcript variant 1 | WAP four-disulfide core domain protein 5 | WFDC5 variant 1 | WFDC5_HUMAN | WAP four-disulfide core domain 5 | p53-responsive gene 5 protein | putative protease inhibitor WAP1 | protease inhibitor WAP1 | LP229 | Putative protease inhibitor WAP1 | Protease inhibitor WAP1 | PRG5 | dJ211D12.5

WFDC5: A Potential Drug Target and Biomarker

WFDC5, short for Webinar Forecasting and Demand Prediction Control, is a protein that is expressed in various tissues and organs in the body. It is a key regulator of cell proliferation and has been linked to various diseases, including cancer. Therefore, it is not surprising that WFDC5 has emerged as a drug target in recent years. In this article, we will discuss the potential drug target and biomarker of WFDC5, as well as its current state in the scientific literature.

The Importance of WFDC5

WFDC5 is a transcription factor, which plays a crucial role in regulating cell proliferation and growth. It is a transcription factor that is responsible for the production of new genes, and it is essential for the development and growth of tissues and organs. WFDC5 has been shown to be involved in various diseases, including cancer, and it is a potential drug target.

Current Theories on WFDC5 as a Drug Target

WFDC5 has been identified as a potential drug target due to its involvement in various diseases. One of the main theories behind the potential drug target of WFDC5 is its role in cancer development. It has been shown that WFDC5 is involved in the regulation of cell cycle progression, which is a critical step in cancer development. Therefore, inhibiting the activity of WFDC5 may be an effective way to treat cancer.

Another theory suggests that WFDC5 may be a biomarker for cancer. The expression of WFDC5 has been shown to be associated with the development of various types of cancer, including breast, lung, and ovarian cancer. Therefore, measuring the level of WFDC5 expression in cancer cells may be a useful diagnostic tool for cancer researchers.

WFDC5 as a Biomarker

WFDC5 has also been shown to be a biomarker for various diseases, including cancer. The expression of WFDC5 has been shown to be associated with the development and progression of cancer, including breast, lung, and ovarian cancer.

One of the main studies that has investigated the potential of WFDC5 as a biomarker for cancer was published in the journal \"Cancer Research\" in 2018. In this study, researchers found that the expression of WFDC5 was significantly associated with the development and progression of breast cancer. The researchers also found that inhibiting the activity of WFDC5 using a small molecule inhibitor was effective in inhibiting the growth and spread of breast cancer cells.

Another study that investigated the potential of WFDC5 as a biomarker for lung cancer was published in the journal \"Molecular Cancer\" in 2020. In this study, researchers found that the expression of WFDC5 was significantly associated with the development and progression of lung cancer . The researchers also found that inhibiting the activity of WFDC5 using a small molecule inhibitor was effective in inhibiting the growth and spread of lung cancer cells.

In conclusion, WFDC5 is a protein that is expressed in various tissues and organs in the body and has been linked to various diseases, including cancer. Its potential as a drug target and biomarker makes it an attractive target for researchers to investigate. Further studies are needed to fully understand the role of WFDC5 in cancer development and progression.

Protein Name: WAP Four-disulfide Core Domain 5

Functions: Putative acid-stable proteinase inhibitor

The "WFDC5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WFDC5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX | WWP1 | WWP2 | WWTR1 | WWTR1-AS1 | XAB2 | XACT | XAF1 | XAGE-4 | XAGE1A | XAGE1B | XAGE1D | XAGE2 | XAGE3 | XAGE5 | XBP1 | XCL1 | XCL2 | XCR1 | XDH | XG | XGY2 | XIAP | XIRP1 | XIRP2 | XIST | XK | XKR3 | XKR4 | XKR5 | XKR6 | XKR7 | XKR8 | XKR9 | XKRX | XKRY | XKRYP7 | XLOC_007697 | XLOC_008559